[{"id":"b5e16538-f022-4496-bc0f-845df258feb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01942837","created_at":"2021-01-18T08:47:53.085Z","updated_at":"2024-07-02T16:36:01.969Z","phase":"Phase 2","brief_title":"Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT01942837","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" SPOP","pipe":" | ","alterations":" AR mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 09/13/2013","start_date":" 09/13/2013","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2022-10-24"},{"id":"4f6d93b4-be3f-49d8-99d0-e1e8eb726d81","acronym":"PSMA-BAT","url":"https://clinicaltrials.gov/study/NCT04424654","created_at":"2021-07-05T17:30:35.370Z","updated_at":"2024-07-02T16:36:06.125Z","phase":"Phase 2","brief_title":"Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy","source_id_and_acronym":"NCT04424654 - PSMA-BAT","lead_sponsor":"Hospital Sirio-Libanes","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2022-08-03"},{"id":"86014f68-4a3e-49b8-af42-63a4717724a7","acronym":"BARRIER-P","url":"https://clinicaltrials.gov/study/NCT02429193","created_at":"2021-01-18T11:37:20.503Z","updated_at":"2024-07-02T16:36:51.426Z","phase":"Phase 2","brief_title":"Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA","source_id_and_acronym":"NCT02429193 - BARRIER-P","lead_sponsor":"University Health Network, Toronto","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR expression • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR expression • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 09/01/2019","study_completion_date":" 09/01/2019","last_update_posted":"2020-01-13"},{"id":"1a7ccaaf-9044-4f2f-ae35-54a15ea11dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393730","created_at":"2021-01-18T05:43:26.209Z","updated_at":"2024-07-02T16:37:13.008Z","phase":"Phase 2","brief_title":"Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT01393730","lead_sponsor":"Mary-Ellen Taplin, MD","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR T878A • AR amplification","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR T878A • AR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 03/15/2017","study_completion_date":" 03/15/2017","last_update_posted":"2018-03-15"}]